What question did this study set out to answer?

The aim is to explore the effectiveness of iron(III) complexes with specific ligands as MRI contrast agents.

February 27, 2026Open Access

NODESINNDIANAD3. 1Patent on Fe (III) -based MRI contrast agents

The aim is to explore the effectiveness of iron(III) complexes with specific ligands as MRI contrast agents.
Synthesis of 1,4-Bis-(2-hydroxy-benzyl)-1,4,7-triazacyclononane derivatives.
Characterization of iron(III) complexes with these ligands.
Evaluation of their efficacy as MRI contrast agents.
Demonstrated improved contrast in MRI imaging with iron(III) complexes.
Specific ligand modifications enhanced binding and imaging properties.

1,4-Bis-(2-hydroxy-benzyl)-1,4,7-triazacyclononane derivatives and similarcompounds as ligands in iron(III) complexes for use as MRI contrast agents

Bookmark

View Full Paper

Mauro Gastón Nacimento Botta (Wed,) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark

View Full Paper